Greg Glenn

Gregory M. Glenn, MD, is CEO of Pinion Immunotherapeutics, a Maryland biotech company using mRNA-LNP as immunotherapeutics to cure chronic viral diseases and cancers. With 30 years in biotech, and recently as President of R&D at Novavax, he helped bring to market vaccines now deployed worldwide, including NUVAXOVID (COVID-19) and the R21/Matrix-M malaria vaccine, used across Africa. Earlier, he founded IOMAI Corporation (acquired by Intercell), after training in basic and translational research at the Walter Reed Army Institute of Research as a U.S. Army physician, and was discharged as a Lt. Col. He holds a B.A. from Whitman College, a Dip.CS from Regent College, and an M.D. from Oral Roberts University School of Medicine. He was a board-certified pediatrician and practiced medicine before entering an R&D track. He believes in the scientific method as a means to explore God’s creation, to understand health and disease, and search for cures that can alleviate suffering. He has authored ~150 primary research and review articles. He is a member and Elder at Fourth Presbyterian Church in Bethesda, MD.